Chronic myeloid leukemia (CML) is the outcome of constitutive tyrosine kinase BCR-Abl enzyme activity, the product of the bcr-abl gene fusion present in the Philadelphia chromosomes of patients whom suffer from CML [1]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.